Erratum: Progress and prospects: Gene therapy clinical trials (part 1) (Gene Therapy (2007) vol. 14 (1439-1447) 10.1038/sj.gt.3303001);Progress and prospects: Gene therapy clinical trials (part 1)

Gene Therapy

Volumn 14, Issue 20, 2007, Pages 1439-1447

  Alton, Eric ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA 1 ANTITRYPSIN; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DYSTROPHIN; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 4; GANCICLOVIR; GENE THERAPY AGENT; GLUTAMATE DECARBOXYLASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOSUPPRESSIVE AGENT; LEVODOPA; LIPOSOME; NEURTURIN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PARVOVIRUS VECTOR; PEPTIDASE; PIGMENT EPITHELIUM DERIVED FACTOR; SARCOGLYCAN; THYMIDINE KINASE; TRANSCRIPTION FACTOR E2F; VASCULOTROPIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANTIINFLAMMATORY ACTIVITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; CORONARY ARTERY DISEASE; CYSTIC FIBROSIS; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DUCHENNE MUSCULAR DYSTROPHY; EYE INFLAMMATION; GENE REPLACEMENT THERAPY; GENE THERAPY; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; LIMB ISCHEMIA; LOW DRUG DOSE; LYSOSOME STORAGE DISEASE; METACHROMATIC LEUKODYSTROPHY; MUCOPOLYSACCHARIDOSIS TYPE 7; MULTIPLE CYCLE TREATMENT; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARKINSON DISEASE; PERIPHERAL VASCULAR DISEASE; PLASMID; PRIORITY JOURNAL; RETINA DEGENERATION; RETINA MACULA AGE RELATED DEGENERATION; RETINOBLASTOMA; REVIEW; SINGLE DRUG DOSE; STEM CELL GENE THERAPY; SUICIDE GENE THERAPY; UNSPECIFIED SIDE EFFECT; VEIN GRAFT DISEASE; VIRAL GENE DELIVERY SYSTEM;

EID: 34848902043     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3303075     Document Type: Erratum

References (47)

1. Chevez-Barrios P, Chintagumpala M, Mieler W, Paysse E, Boniuk M, Kozinetz C et al. Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J Clin Oncol 2005; 23: 7927-7935.
2. Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: Results of a phase I clinical trial. Hum Gene Ther 2006; 17: 167-176.
3. Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, Cideciyan AV et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001; 28: 92-95.
4. Narfstrom K, Katz ML, Ford M, Redmond TM, Rakoczy E, Bragadottir R. In vivo gene therapy in young and adult RPE65-/- dogs produces long-term visual improvement. J Hered 2003; 94: 31-37.
5. Le Meur G, Stieger K, Smith AJ,Weber M, Deschamps JY, Nivard D et al. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Therapy 2007; 14: 292-303.
6. Boyd AC. Gene and Stem Cell Therapy. In: Bush A, Alton EWFW, Davies JC, Griesenbach U, Jaffe A (eds). Cystic Fibrosis in the 21st Century, 2006, Karger: Basel, pp 221-229.
7. Harvey BG, Leopold PL, Hackett NR, Grasso TM, Williams PM, Tucker AL et al. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest 1999; 104: 1245-1255.
8. Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: A multicenter, double-blind, placebo-controlled trial. Chest 2004; 125: 509-521.
9. Hyde SC, Southern KW, Gileadi U, Fitzjohn EM, Mofford KA, Waddell BE et al. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Therapy 2000; 7: 1156-1165.
10. Brigham KL, Lane LB, Meyrick B, Stecenko AA, Stack S, Cannon DR et al. Transfection of nasal mucosa with a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: Comparison with protein therapy. Hum Gene Ther 2000; 11: 1023-1032.
11. Song S, Morgan M, Ellis T, Porrier A, Chesnut K, Wang J et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA 1998; 95: 14384-14388.
12. Brantly ML, Spencer LT, Humphries M, Conlon TJ, Spencer CT, Poirrier A et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alpha(1)-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 2006; 17: 1177-1186.
13. Manno CS, Pierce GF, Arruda VR, Glader B, Raghi M, Rasko JJ et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
14. Arruda VR, Stedman HH, Nichols TC, Haskins ME, Nicholson M, Herzog RW et al. Regional intravascular delivery of AAV-2-F. IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood 2005; 105: 3458-3464.
15. Romero NB, Braun S, Benveniste O, Leturcq F, Hogrel JY, Morris GE et al. Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy. Hum Gene Ther 2004; 15: 1065-1076.
16. Stedman H, Wilson JM, Finke R, Kleckner AL, Mendell J. Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: Alpha-, beta-, gamma-, or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors. J Hum Gene Ther 2000; 11: 777-790.
17. Takeshima Y, Yagi M, Wada H, Ishibashi K, Nishiyama A, Kakumoto M et al. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr Res 2006; 59: 690-694.
18. van Deutekom JC. Gene therapy: The 'pro-sense' approach to Duchenne muscular dystrophy. Eur J Hum Genet 2005; 13: 518-519.
19. + cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum Gene Ther 1998; 9 2629-2640.
20. + hematopoietic progenitor cell-directed lentiviral-mediated gene therapy in a xenotransplantation model of lysosomal storage disease. Mol Ther 2004; 9: 856-865.
21. Liang SB, Yoshimitsu M, Poeppl A, Rasaiah VI, Cai J, Fowler DH et al. Multiple reduced-intensity regimens facilitate correction of Fabry mice after transplantation of transduced cells. Mol Ther 2007; 15: 618-627.
22. Sands MS, Davidson BL. Gene therapy for lysosomal storage diseases. Mol Ther 2006; 13: 839-849.
23. Crystal RG, Sondhi D, Hackett NR, Kaminsky SM, Worgall S, Stieg P et al. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther 2004; 15: 1131-1154.
24. Cavazzana-Calvo M, Hacein-Bey S, de Saint BG, Gross F, Yvon E, Nusbaum P et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672.
25. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346: 1185-1193.
26. Hacein-Bey-Abina S, von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302 415-419.
27. Thrasher AJ, Gaspar HB, Baum C, Modlich U, Schambach A, Candotti F et al. Gene therapy: X-SCID transgene leukaemogenicity. Nature 2006; 443: E5-E6.
28. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410-2413.
29. Gaspar HB, Bjorkegren E, Parsley K, Gilmour KC, King D, Sinclair J et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther 2006; 14: 505-513.
30. Heyworth PG, Cross AR, Curnutte JT. Chronic granulomatous disease. Curr Opin Immunol 2003; 15: 578-584.
31. Malech HL, Maples PB, Whiting-Theobald N, Linton GF, Sekhsaria S, Vowells SJ et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci USA 1997; 94: 12133-12138.
32. Malech HL, Horwitz ME, Linton GF, Al E. Extended production of oxidase normal neutrophils in X-linked chronic granulomatous disease following gene therapy with gp91phox transduced CD34+ cells. Blood 1998; 92 (Suppl 1): 690a.
33. Barese CN, Goebel WS, Dinauer MC. Gene therapy for chronic granulomatous disease. Expert Opin Biol Ther 2004; 4: 1423-1434.
34. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS/EVI1, PRDM16 or SETBP1. Nat Med 2006; 12: 401-409.
35. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA et al. Safety and Tolerability of AAV-GAD gene therapy for Parkinson's disease: An open-label, phase I trial. Lancet 2007; 369: 2097-2105.
36. Kordower JH, Herzog CD, Dass B, Bakay RA, Stansell III J, Gasmi M et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 2006; 60: 706-715.
37. Bankiewicz KS, Forsayeth J, Eberling JL, Sanchez-Pernaute R, Pivirotto P, Bringas J et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 2006; 14: 564-570.
38. Kastrup J, Jorgensen E, Ruck A, Tagil K, Glogar D, Ruzyllo W et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: The Euroinject One trial. J Am Coll Cardiol 2005; 45: 982-988.
39. Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: A phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Therapy 2006; 13: 1503-1511.
40. Simons M. Angiogenesis: Where do we stand now? Circulation 2005; 111: 1556-1566.
41. Yla-Herttuala S. An update on angiogenic gene therapy: Vascular endothelial growth factor and other directions. Curr Opin Mol Ther 2006; 8: 295-300.
42. Sasso FC, Torella D, Carbonara O, Ellison GM, Torella M, Scardone M et al. Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J Am Coll Cardiol 2005; 46: 827-834.
43. Mäkinen K, Manninen H, Hedman M, Matsi P, Mussalo H, Alhava E et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: A randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002; 6: 127-133.
44. Rajagopalan S, Mohler III ER, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108: 1933-1938.
45. Kusumanto YH, van Weel V, Mulder NH, Smit AJ, van den Dungen JJ, Hooymans JM et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: A double-blind randomized trial. Hum Gene Ther 2006; 17: 683-691.
46. Nikol S, Baumgartner I, van Belle E, Diehm C, Visona A, Capogrossi MC et al. Therapeutic angiogenesis with intramuscular NVIFGF improves amputation-free survival in patients with critical limb ischemia. American College of Cardiology 55th Annual Scientific Session, Abstract 405-410, Vol. 47, 2006.
47. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ et al. Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 2006; 43: 742-751.